Patent · US Active

Bifunctional fusion protein against PDL1 and TGFβ and use thereof

US12325748B2 · kind B2 · utility

0Cited by

0References

6Claims

0Family size

Assignee

Shandong Boan Biotechnology Co., Ltd. · CN

Inventors

Deyong SONG · Shandong, CN
Hongguang Xu · Yantai, CN
Zhen Han · Beijing, CN

Key dates

Filing date	Jun 8, 2020
Grant date	Jun 10, 2025
Priority date	—
Expiry date	Sep 1, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are an anti-PDL1 antibody and an antigen-binding fragment thereof, and further provided are a bifunctional fusion protein against PDL1 and TGFβ and a preparation method thereof and the use thereof. The antibody or antigen-binding fragment or the bifunctional fusion protein has one or more of the following advantages: an enhanced TGFβ1 binding activity, an enhanced affinity to PDL1, an enhanced ability to block the binding of PDL1 and PD1, an enhanced functional activity for blocking TGFβ 1, an enhanced ability to promote the secretion of IFN-γ by T cells, a better immunomodulatory effect and a better tumor inhibitory effect.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.